# Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT

> **NCT06334367** · PHASE2 · UNKNOWN · sponsor: **Wang Xin** · enrollment: 40 (estimated)

## Conditions studied

- GVHD

## Interventions

- **DRUG:** CD25 treatment
- **DRUG:** low-dose ATG

## Key facts

- **NCT ID:** NCT06334367
- **Lead sponsor:** Wang Xin
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-26
- **Primary completion:** 2026-03-26
- **Final completion:** 2026-03-26
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06334367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06334367, "Prophylaxis of Graft-versus-host Disease With Anti-CD25 Antibody in Patients Underwent HSCT". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06334367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*